11.1 Information on toxicological effects
Acute toxicity
Oral: absorption
LD50 Oral - Rat - male and female - 1.453 mg/kg (OECD Test Guideline 401)
The value is given in analogy to the following substances: Sodium tungstate
LC50 Inhalation - Rat - male and female - 4 h - > 5,01 mg/l - dust/mist (OECD Test Guideline 403)
LD50 Dermal - Rat - male and female - > 2.000 mg/kg (OECD Test Guideline 402)
Skin corrosion/irritation
Skin - Rabbit
Result: No skin irritation - 4 h (OECD Test Guideline 404)
Serious eye damage/eye irritation
Eyes - Rabbit
Result: slight irritation (OECD Test Guideline 405)
Respiratory or skin sensitization
Maximization Test - Guinea pig
Result: negative (OECD Test Guideline 406)
The value is given in analogy to the following substances: Sodium tungstate
Germ cell mutagenicity
Test Type: Mutagenicity (mammal cell test): chromosome aberration.
Test system: Chinese hamster ovary cells
Metabolic activation: with and without metabolic activation
Method: OECD Test Guideline 473
Result: negative
Test Type: In vitro mammalian cell gene mutation test
Test system: Mouse lymphoma test
Metabolic activation: with and without metabolic activation
Method: OECD Test Guideline 476
Result: negative
Test Type: Ames test
Test system: Escherichia coli/Salmonella typhimurium
Metabolic activation: with and without metabolic activation
Method: OECD Test Guideline 471
Result: negative
Test Type: Mutagenicity (mammal cell test): micronucleus.
Species: Mouse
Cell type: Bone marrow
Application Route: Oral
Method: OECD Test Guideline 474
Result: negative
Carcinogenicity
Classified based on available data. For more details, see section 2
Reproductive toxicity
Classified based on available data. For more details, see section 2
Specific target organ toxicity - single exposure
Classified based on available data. For more details, see section 2
Specific target organ toxicity - repeated exposure
Classified based on available data. For more details, see section 2
Aspiration hazard
Classified based on available data. For more details, see section 2
11.2 Additional Information
Endocrine disrupting properties
Product:
Assessment : The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.
RTECS: YO7900000
To the best of our knowledge, the chemical, physical, and toxicological properties have not been thoroughly investigated.
After absorption:
Gastrointestinal disturbance
Other dangerous properties can not be excluded.
Handle in accordance with good industrial hygiene and safety practice.